Last reviewed · How we verify
Paroxetine treatment during 8 weeks
At a glance
| Generic name | Paroxetine treatment during 8 weeks |
|---|---|
| Also known as | Placebo treatment during 8 weeks |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study on Functional Connectome and rTMS Intervention of Cognitive Flexibility Impairment in Patients With Major Depressive Disorder (NA)
- Sequenced Treatment Effectiveness for Posttraumatic Stress (PHASE4)
- Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen (NA)
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder (PHASE3)
- A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Depression (NA)
- Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients (PHASE4)
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD (PHASE4)
- Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paroxetine treatment during 8 weeks CI brief — competitive landscape report
- Paroxetine treatment during 8 weeks updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI